These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 4859014

  • 21. [Therapeutic association of L-dopa and an inhibitor of peripheral decarboxylase in Parkinsonism. Preliminary results].
    De Divitiis E, Cerillo A, Tata MR, Decina A.
    Acta Neurol (Napoli); 1973; 28(2):208-12. PubMed ID: 4709076
    [No Abstract] [Full Text] [Related]

  • 22. [Treatment of parkinsonism by L-dopa and dopa-decarboxylase inhibitor in a single tablet].
    Sarova-Pinhas I, Braham J.
    Harefuah; 1974 Sep 01; 87(5):208-10. PubMed ID: 4435614
    [No Abstract] [Full Text] [Related]

  • 23. Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602).
    Chouza C, Romero S, Gomensoro JB.
    Acta Neurol Latinoam; 1974 Sep 01; 20(1-4):116-38. PubMed ID: 4619960
    [No Abstract] [Full Text] [Related]

  • 24. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F, Mentasti M, Riederer P, Birkmayer W.
    Wien Klin Wochenschr; 1979 May 11; 91(10):332-7. PubMed ID: 452602
    [Abstract] [Full Text] [Related]

  • 25. [Advantages of the combination therapy (L-Dopa and decarboxylase inhibitors) in parkinsonism].
    Gattringer B, Steinhäusl H.
    Wien Med Wochenschr; 1972 Jun 17; 122(25):369-71. PubMed ID: 4558132
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Improvement in mono-manual dexterity in parkinsonism when supplementing levodopa with an extracerebral decarboxylase inhibitor, RO 4-4602.
    Knutsson E, Mårtensson A.
    Scand J Rehabil Med; 1974 Jun 17; 6(2):89-93. PubMed ID: 4837060
    [No Abstract] [Full Text] [Related]

  • 34. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
    Admani AK, Verma S, Cordingley GJ, Harris RI.
    Pharmatherapeutica; 1985 Jun 17; 4(2):132-40. PubMed ID: 4059292
    [Abstract] [Full Text] [Related]

  • 35. Treatment of Parkinsonism with a compound of L-dopa (Larodopa R) and a decarboxylase inhibitor (RO-46-4602).
    Holmsen R, Kvan L, Presthus J, Thoresen GB.
    Acta Neurol Scand Suppl; 1972 Jun 17; 51():121-2. PubMed ID: 4514336
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Study of deterioration in long-term treatment of parkinsonism with L-dopa plus decarboxylase inhibitor.
    Ludin HP, Bass-Verrey F.
    J Neural Transm; 1976 Jun 17; 38(3-4):249-58. PubMed ID: 956811
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.